These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23624296)

  • 1. Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression.
    Mehta D; Raison CL; Woolwine BJ; Haroon E; Binder EB; Miller AH; Felger JC
    Brain Behav Immun; 2013 Jul; 31():205-15. PubMed ID: 23624296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression.
    Bekhbat M; Chu K; Le NA; Woolwine BJ; Haroon E; Miller AH; Felger JC
    Psychoneuroendocrinology; 2018 Dec; 98():222-229. PubMed ID: 30249443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.
    Raison CL; Rutherford RE; Woolwine BJ; Shuo C; Schettler P; Drake DF; Haroon E; Miller AH
    JAMA Psychiatry; 2013 Jan; 70(1):31-41. PubMed ID: 22945416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis.
    Lequerré T; Gauthier-Jauneau AC; Bansard C; Derambure C; Hiron M; Vittecoq O; Daveau M; Mejjad O; Daragon A; Tron F; Le Loët X; Salier JP
    Arthritis Res Ther; 2006; 8(4):R105. PubMed ID: 16817978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation.
    Weinberger JF; Raison CL; Rye DB; Montague AR; Woolwine BJ; Felger JC; Haroon E; Miller AH
    Brain Behav Immun; 2015 Jul; 47():193-200. PubMed ID: 25529904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression.
    Mansur RB; Delgado-Peraza F; Subramaniapillai M; Lee Y; Iacobucci M; Rodrigues N; Rosenblat JD; Brietzke E; Cosgrove VE; Kramer NE; Suppes T; Raison CL; Chawla S; Nogueras-Ortiz C; McIntyre RS; Kapogiannis D
    Cells; 2020 Apr; 9(4):. PubMed ID: 32268604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of infliximab in treatment-resistant depression: A systematic review and meta-analysis.
    Bavaresco DV; Uggioni MLR; Ferraz SD; Marques RMM; Simon CS; Dagostin VS; Grande AJ; da Rosa MI
    Pharmacol Biochem Behav; 2020 Jan; 188():172838. PubMed ID: 31837338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial.
    McIntyre RS; Subramaniapillai M; Lee Y; Pan Z; Carmona NE; Shekotikhina M; Rosenblat JD; Brietzke E; Soczynska JK; Cosgrove VE; Miller S; Fischer EG; Kramer NE; Dunlap K; Suppes T; Mansur RB
    JAMA Psychiatry; 2019 Aug; 76(8):783-790. PubMed ID: 31066887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
    Louis E; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Malaise M; Belaiche J
    Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients.
    Lindberg J; af Klint E; Catrina AI; Nilsson P; Klareskog L; Ulfgren AK; Lundeberg J
    Arthritis Res Ther; 2006; 8(6):R179. PubMed ID: 17134501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.
    Magnusson MK; Strid H; Isaksson S; Bajor A; Lasson A; Ung KA; Öhman L
    J Crohns Colitis; 2015 Jan; 9(1):56-65. PubMed ID: 25518051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.
    Koutroubakis IE; Oustamanolakis P; Malliaraki N; Karmiris K; Chalkiadakis I; Ganotakis E; Karkavitsas N; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2009 Mar; 21(3):283-8. PubMed ID: 19279474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab).
    Buch MH; Reece RJ; Quinn MA; English A; Cunnane G; Henshaw K; Bingham SJ; Bejarano V; Isaacs J; Emery P
    Rheumatology (Oxford); 2008 Oct; 47(10):1469-75. PubMed ID: 18660510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response.
    Pachot A; Arnaud B; Marrote H; Cazalis MA; Diasparra J; Gouraud A; Mougin B; Miossec P
    J Rheumatol; 2007 Nov; 34(11):2158-61. PubMed ID: 17896807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
    Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
    J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
    Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF
    Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
    Ebert EC; Das KM; Mehta V; Rezac C
    Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.